New drug combo could help men with advanced prostate cancer
A new mix of two drugs—enzalutamide and leuprolide—has been shown to lower the risk of death by 40.3% for men with advanced, returning prostate cancer.
This study with nearly eight years of follow-up, led by Cedars-Sinai Cancer researchers and shared at a major medical conference this weekend, could be a big step forward in cancer treatment.
Study involved over 1,000 patients from 17 countries
Over 1,000 patients from 17 countries took part. They were randomly given either the combo treatment or just one of the drugs.
Only the combination led to longer survival after nearly eight years of follow-up.
Enzalutamide is already FDA-approved and can be used alongside hormone therapy.
Combo brings hope for better outcomes
For decades, men whose prostate cancer came back aggressively had few options—hormone therapy was the main tool, but didn't improve survival much.
With this new combo, there's real hope for better outcomes for those facing high-risk, recurring prostate cancer.